Company Overview and News

 
ASX falls as CBA hits 20-month low

2018-05-21 theage.com.au
Australian shares ended slightly lower as the banking royal commission returned with a focus on small business loans.

 
ASX falls as CBA hits 20-month low

2018-05-21 smh.com.au
Australian shares ended slightly lower as the banking royal commission returned with a focus on small business loans.

 
Wage fraud claims dunk Retail Food Group to bottom of ASX 200

2017-12-18 theage.com.au
Allegations of widespread wage fraud have sunk troubled franchising giant Retail Food Group to the bottom of the S&P ASX 200, putting it at risk of being dropped from the benchmark index.

 
Wage fraud claims dunk Retail Food Group to bottom of ASX 200

2017-12-18 smh.com.au
Allegations of widespread wage fraud have sunk troubled franchising giant Retail Food Group to the bottom of the S&P ASX 200, putting it at risk of being dropped from the benchmark index.

 
Markets Live: Banks, miners boost ASX

2017-12-12 theage.com.au
The ASX is getting a boost from miners and banks today as it trades firmly over 6000 and edges toward a level not seen for two weeks. 

 
Property deal speculation, oil gains boost ASX

2017-12-12 theage.com.au
Higher commodity prices and deal speculation in the property sector pushed the ASX to gains on Tuesday, with the benchmark closing firmly over the 6000 level.

 
Property deal speculation, oil gains boost ASX

2017-12-12 smh.com.au
Higher commodity prices and deal speculation in the property sector pushed the ASX to gains on Tuesday, with the benchmark closing firmly over the 6000 level.

 
Markets Live: Banks, miners boost ASX

2017-12-12 smh.com.au
The ASX is getting a boost from miners and banks today as it trades firmly over 6000 and edges toward a level not seen for two weeks. 

 
ASX in holding pattern as banks slip

2017-10-24 theage.com.au
The Australian sharemarket consolidated around the five-and-half-month high it hit late last week as a two-week run of gains runs out of puff.

 
ASX in holding pattern as banks slip

2017-10-24 smh.com.au
The Australian sharemarket consolidated around the five-and-half-month high it hit late last week as a two-week run of gains runs out of puff.

 
Sale-and-leaseback deal reaps Asaleo Care $22.4m from Perpetual

2017-06-15 theage.com.au
Toilet paper and feminine hygiene product manufacturing giant Asaleo Care –  the subject of a private equity bid which values the company at more than $US20 billion – is banking $22.4 million selling a Springvale industrial asset with a leaseback to Perpetual, a Sydney-based institutional investor.

 
Sale-and-leaseback deal reaps Asaleo Care $22.4m from Perpetual

2017-06-15 smh.com.au
Toilet paper and feminine hygiene product manufacturing giant Asaleo Care –  the subject of a private equity bid which values the company at more than $US20 billion – is banking $22.4 million selling a Springvale industrial asset with a leaseback to Perpetual, a Sydney-based institutional investor.

 
Banks lift ASX to another high

2017-04-11 smh.com.au
The Australian sharemarket defied weak offshore leads and falling iron ore prices to push higher again on Tuesday, with strength in the major banks helping keep the benchmark index at its highest level since early 2015. 

 
Banks lift ASX to another high

2017-04-11 theage.com.au
The Australian sharemarket defied weak offshore leads and falling iron ore prices to push higher again on Tuesday, with strength in the major banks helping keep the benchmark index at its highest level since early 2015. 

 
ASX ends week lower on tumbling metal prices

2017-02-24 theage.com.au
Tumbling metal prices and wobbly global markets dragged the local sharemarket lower on Friday, causing the index to finish the week in the red despite positive earnings results being welcomed by investors.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...